Articles From: AirMedia to Announce Third Quarter 2014 Unaudited Financial Results on November 17, 2014 to Akebia Therapeutics, Inc. Added to NASDAQ Biotechnology Index


Cleve Adams, CEO of AirPatrol Corporation, a Sysorex (NASDAQ:SYRX) subsidiary, and a developer of mobile device detection and locationing systems, has joined the National Initiative for Cybersecurity Education (NICE) Cybersecurity Map’s advisory board.
Sign-up for AirPatrol CEO, Cleve Adams Joins Advisory Board of NICE Cyber Education Map investment picks
More than 70,000 visitors attended the Carlsbad Village Fair on November 2 nd according to numbers gathered by AirPatrol Corporation, a Sysorex Company (NASDAQ: SYRX). The figures, which AirPatrol compiled using technology that counts people based on the “pings” their cellphones emit as they move about, also provided insight into how people traveled through the event, which areas were most popular, and how long they stayed.
Sign-up for AirPatrol Technology Counts More Than 70,000 Visitors to San Diego County’s Carlsbad Village Fair investment picks
In a strategic alliance, Sysorex (NASDAQ:SYRX) subsidiary AirPatrol Corporation, a developer of mobile device detection and locationing systems, and Cubeware GmbH, a leading provider of business intelligence and analytics software in Europe, today announced that they are offering an integrated next generation big data analytics platform focused on gaining business insights based on where, how and when people use mobile devices.
Sign-up for AirPatrol, a Sysorex Company, and Cubeware GmbH Announce Strategic Alliance for Mobile Analytics investment picks
2014/12/30
By I Made Sentana JAKARTA, Indonesia--The search for a missing AirAsia jet that vanished in storm clouds over Indonesia appeared closer to a breakthrough Tuesday, as officials said airplane debris had been found in waters near the island of Borneo.
Sign-up for Airplane Debris Found Off Island of Borneo, Officials Say investment picks
2014/12/30
By I Made Sentana JAKARTA, Indonesia--The search for a missing AirAsia jet appeared closer to a breakthrough Tuesday, as Indonesian officials said airplane debris had been found in waters near the island of Borneo, and the head of the search effort said he was "95%" certain that it was from the missing plane.
Sign-up for Airplane Debris Found Off Island of Borneo, Officials Say -- 3rd Update investment picks
2014/12/30
By I Made Sentana JAKARTA, Indonesia--The search for a missing AirAsia jet that vanished in storm clouds over Indonesia appeared closer to a breakthrough Tuesday, as officials said airplane debris had been found in waters near the island of Borneo.
Sign-up for Airplane Debris Found Off Island of Borneo, Officials Say -- Update investment picks
WEST CHESTER, Ohio , Dec.
Sign-up for AK Steel Announces Fourth Quarter and Full-Year 2014 Earnings Date investment picks
WEST CHESTER, Ohio , Oct.
Sign-up for AK Steel Announces Price Increase For Carbon Steel Products investment picks
WEST CHESTER, Ohio , Dec.
Sign-up for AK Steel Provides Fourth Quarter 2014 Guidance investment picks
WEST CHESTER, Ohio , Nov.
Sign-up for AK Steel Reports Financial Results For Third Quarter Of 2014 investment picks
WEST CHESTER, Ohio , Dec.
Sign-up for AK Steel Successfully Completes Ashland Blast Furnace Hearth Reline and Resumes Full Production investment picks
WEST CHESTER, Ohio , Nov.
Sign-up for AK Steel Wins Trade Cases on Non-Oriented Electrical Steel investment picks
New self-service Akamai Community uses market-leading JiveX solution to promote best practices in online content delivery PALO ALTO, Calif.
Sign-up for Akamai Launches Jive-powered Customer Community To Help Thousands Of Businesses Accelerate Innovation investment picks
Experienced leader in real estate management and operations, Chapman has led corporate services divisions at OSRAM, inVentiv Health, and adidas Group CAMBRIDGE, Mass.
Sign-up for Akamai Names Erica Chapman as Vice President of Corporate Services investment picks
DDoS attacks surge: Four-fold year-over-year increase in DDoS attack size and volume; Thriving criminal industry taps into Internet devices, spreads easy-to-use tools CAMBRIDGE, Mass.
Sign-up for Akamai PLXsert's Q3 2014 State of the Internet - Security Report Released investment picks
CAMBRIDGE, Mass.
Sign-up for Akamai Releases Third Quarter 2014 'State of the Internet' Report investment picks
CAMBRIDGE, Mass.
Sign-up for Akamai Reports Third Quarter 2014 Financial Results investment picks
New Capabilities Geared Toward Operational Efficiency Bolster Industry-leading Application Acceleration, Optimization and Security CAMBRIDGE, Mass.
Sign-up for Akamai Tailors Web Performance Solutions for SaaS Providers investment picks
CAMBRIDGE, Mass.
Sign-up for Akamai Technologies To Participate In The Credit Suisse Technology Conference investment picks
Crime kit used on machines compromised by Zeus and other malware Malicious actors alter webpages to steal information from banking users CAMBRIDGE, Mass.
Sign-up for Akamai Warns of Yummba Webinject Tools and Banking Fraud investment picks
NCR Corporation (NYSE: NCR), the global leader in consumer transaction technologies, announced today that Akbank has selected innovative Predictive Services technology from NCR to help increase the availability of its ATMs across Turkey.
Sign-up for Akbank chooses NCR to Further Increase ATM Availability and Enhance Customer Experience investment picks
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced positive top-line results from its Phase 2b placebo-controlled trial of AKB-6548 in non-dialysis patients with anemia related to chronic kidney disease (CKD). The study achieved its primary endpoint and AKB-6548 was generally well tolerated, confirming that the once-daily, oral therapy can successfully increase and maintain hemoglobin (HGB) levels.
Sign-up for Akebia Announces Positive Top-Line Results from its Phase 2b Study of AKB-6548 in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease investment picks
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that data from the AKB-6548 development program will be presented in two poster sessions at the upcoming American Society of Nephrology (ASN) Kidney Week 2014 annual meeting in Philadelphia, PA from November 11-16, 2014.
Sign-up for Akebia Announces Poster Presentations at the Upcoming American Society of Nephrology Kidney Week 2014 Annual Meeting investment picks
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced financial results for the third quarter ended September 30, 2014.
Sign-up for Akebia Announces Third Quarter 2014 Financial Results investment picks
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that it has completed enrollment ahead of schedule in the original two cohorts of its Phase 2 clinical study evaluating AKB-6548, a once-daily, oral therapy, in patients with anemia related to chronic kidney disease (CKD) who are undergoing dialysis.
Sign-up for Akebia Completes Enrollment in the Two Planned Cohorts of its Phase 2 Study of AKB-6548 in Patients with Anemia Related to Chronic Kidney Disease Undergoing Dialysis investment picks
Akebia Therapeutics, Inc. (NASDAQ: AKBA ), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), announced today that John P.
Sign-up for Akebia Therapeutics President and Chief Executive Officer Establishes Stock Purchase Plan investment picks
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that it has been selected for addition to the NASDAQ Biotechnology Index ® (Nasdaq:^NBI). The annual re-ranking of the NASDAQ Biotechnology Index will become effective upon market open on Monday, December 22, 2014.
Sign-up for Akebia Therapeutics, Inc. Added to NASDAQ Biotechnology Index investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: AirMedia to Announce Third Quarter 2014 Unaudited Financial Results on November 17, 2014 to Akebia Therapeutics, Inc. Added to NASDAQ Biotechnology Index
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent